{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:20:27Z","timestamp":1775265627395,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1007\/s40262-018-0720-z","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T06:12:27Z","timestamp":1541571147000},"page":"875-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications"],"prefix":"10.1007","volume":"58","author":[{"given":"Carla","family":"Carnovale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faizan","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Mosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabri\u00eblla G. A. M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,7]]},"reference":[{"key":"720_CR1","unstructured":"World Health Organization. Epilepsy. Available at: http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/epilepsy. Accessed 27 Apr 2018."},{"issue":"1","key":"720_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","volume":"10","author":"C Johannessen Landmark","year":"2010","unstructured":"Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119\u201340.","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"720_CR3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473\u201381.","journal-title":"Lancet Neurol."},{"issue":"3","key":"720_CR4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2006","unstructured":"Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246\u201355.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"720_CR5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00002018-199819060-00006","volume":"19","author":"P Loiseau","year":"1998","unstructured":"Loiseau P. Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance. Drug Saf. 1998;19(6):495\u2013510.","journal-title":"Drug Saf"},{"issue":"1","key":"720_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.01.027","volume":"50","author":"S Esposito","year":"2017","unstructured":"Esposito S, Canevini MP, Principi N. Complications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugs. Int J Antimicrob Agents. 2017;50(1):1\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"720_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40272-016-0167-3","volume":"18","author":"S Strazzer","year":"2016","unstructured":"Strazzer S, Pozzi M, Avantaggiato P, Zanotta N, Epifanio R, Beretta E, et al. Late post-traumatic epilepsy in children and young adults: impropriety of long-term antiepileptic prophylaxis and risks in tapering. Paediatr Drugs. 2016;18(3):235\u201342.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"720_CR8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.spen.2010.10.003","volume":"17","author":"CJ Chu-Shore","year":"2010","unstructured":"Chu-Shore CJ, Thiele EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol. 2010;17(4):214\u201323.","journal-title":"Semin Pediatr Neurol."},{"issue":"7","key":"720_CR9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/11630700-000000000-00000","volume":"35","author":"R Guerrini","year":"2012","unstructured":"Guerrini R, Zaccara G, la Marca G, Rosati A. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf. 2012;35(7):519\u201333.","journal-title":"Drug Saf."},{"key":"720_CR10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","volume":"69","author":"JJ Shih","year":"2017","unstructured":"Shih JJ, Whitlock JB, Chimato N, Vargas E, Karceski SC, Frank RD. Epilepsy treatment in adults and adolescents: expert opinion, 2016. Epilepsy Behav. 2017;69:186\u2013222.","journal-title":"Epilepsy Behav."},{"issue":"1-02","key":"720_CR11","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9\u201362.","journal-title":"Pharmacopsychiatry."},{"issue":"4","key":"720_CR12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","volume":"18","author":"CJ Landmark","year":"2016","unstructured":"Landmark CJ, Johannessen SI, Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016;18(4):367\u201383.","journal-title":"Epileptic Disord."},{"issue":"4","key":"720_CR13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2710.2006.00743.x","volume":"31","author":"S Fudio","year":"2006","unstructured":"Fudio S, Carcas A, Pi\u00f1ana E, Ortega R. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J Clin Pharm Ther. 2006;31(4):393\u20136.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"720_CR14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/42.4.563","volume":"42","author":"BJ De Turck","year":"1998","unstructured":"De Turck BJ. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998;42(4):563\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"720_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archneur.1985.04060020105023","volume":"42","author":"E Carranco","year":"1985","unstructured":"Carranco E, Kareus J, Co S, Peak V, Al-Rajeh S. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol. 1985;42(2):187\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"720_CR16","first-page":"147","volume":"47","author":"WH Berrettini","year":"1986","unstructured":"Berrettini WH. A case of erythromycin-induced carbamazepine toxicity. J Clin Psychiatry. 1986;47(3):147.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"720_CR17","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1128\/AAC.45.9.2543-2552.2001","volume":"45","author":"EJ Randinitis","year":"2001","unstructured":"Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, et al. Drug interactions with clinafloxacin. Antimicrob Agents Chemother. 2001;45(9):2543\u201352.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"720_CR18","first-page":"151","volume":"37","author":"H Albin","year":"1982","unstructured":"Albin H, Vin\u00e7on G, Pehourcq F, Dangoumau J. Influence of josamycine treatment on carbamazepine kinetics. Therapie. 1982;37(2):151\u20136.","journal-title":"Therapie."},{"issue":"6","key":"720_CR19","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2125.1987.tb03257.x","volume":"24","author":"N Barzaghi","year":"1987","unstructured":"Barzaghi N, Gatti G, Crema F, Monteleone M, Amione C, Leone L, et al. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol. 1987;24(6):836\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"720_CR20","first-page":"101","volume":"8","author":"N Barzaghi","year":"1988","unstructured":"Barzaghi N, Gatti G, Crema F, Faja A, Monteleone M, Amione C, et al. Effect of flurithromycin, a new macrolide antibiotic, on carbamazepine disposition in normal subjects. Int J Clin Pharmacol Res. 1988;8(2):101\u20135.","journal-title":"Int J Clin Pharmacol Res"},{"issue":"2","key":"720_CR21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00007691-199003000-00006","volume":"12","author":"W Couet","year":"1990","unstructured":"Couet W, Istin B, Ingrand I, Girault J, Fourtillan JB. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Ther Drug Monit. 1990;12(2):144\u20139.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"720_CR22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/clpt.1983.62","volume":"33","author":"YY Wong","year":"1983","unstructured":"Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther. 1983;33(4):460\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"720_CR23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S031716710002775X","volume":"15","author":"KJ Goulden","year":"1988","unstructured":"Goulden KJ, Camfield PR, Camfield CS, Tibbles JA, Dooley JM, Fraser AD, et al. Changes in serum anticonvulsant levels with febrile illness in children with epilepsy. Can J Neurol Sci. 1988;15(3):281\u20135.","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"720_CR24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1980.tb04300.x","volume":"21","author":"E Mesdjian","year":"1980","unstructured":"Mesdjian E, Dravet C, Cenraud B, Roger J. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia. 1980;21(5):489\u201396.","journal-title":"Epilepsia."},{"issue":"6","key":"720_CR25","first-page":"489","volume":"7","author":"NK O\u2019Connor","year":"1994","unstructured":"O\u2019Connor NK, Fris J. Clarithromycin-carbamazepine interaction in a clinical setting. J Am Board Fam Pract. 1994;7(6):489\u201392.","journal-title":"J Am Board Fam Pract"},{"issue":"3","key":"720_CR26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00607583","volume":"32","author":"G Vin\u00e7on","year":"1987","unstructured":"Vin\u00e7on G, Albin H, Demotes-Mainard F, Guyot M, Bistue C, Loiseau P. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol. 1987;32(3):321\u20133.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"720_CR27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1528-1157.1993.tb02391.x","volume":"34","author":"F Albani","year":"1993","unstructured":"Albani F, Riva R, Baruzzi A, Genton P, Portera-Sanchez A, Lipinski CG. Clarithromycin-carbamazepine interaction: a case report. Epilepsia. 1993;34(1):161\u20132.","journal-title":"Epilepsia."},{"issue":"8015","key":"720_CR28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(77)93005-7","volume":"1","author":"C Dravet","year":"1977","unstructured":"Dravet C, Mesdjian E, Cenraud B, Roger J. Interaction between carbamazepine and triacetyloleandomycin. Lancet. 1977;1(8015):810\u20131.","journal-title":"Lancet"},{"issue":"11","key":"720_CR29","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0035-3787(07)74183-8","volume":"163","author":"P G\u00e9lisse","year":"2007","unstructured":"G\u00e9lisse P, Hillaire-Buys D, Halaili E, Jean-Pastor MJ, Vespignan H, Coubes P, et al. Carbamazepine and clarithromycin: a clinically relevant drug interaction. Rev Neurol (Paris). 2007;163(11):1096\u20139.","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"720_CR30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0022-3476(86)80593-5","volume":"109","author":"KJ Goulden","year":"1986","unstructured":"Goulden KJ, Camfield P, Dooley JM, Fraser A, Meek DC, Renton KW, et al. Severe carbamazepine intoxication after coadministration of erythromycin. Clinical and laboratory observations. J Pediatr. 1986;109(1):135\u20138.","journal-title":"J Pediatr"},{"issue":"10","key":"720_CR31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.revmed.2005.05.014","volume":"26","author":"V Leclercq","year":"2005","unstructured":"Leclercq V, Lacaille S, Delpierre S, Karoubi E, Legrain S. Avoidable adverse event: carbamazepine encephalopathy when introducing clarithromycine. Rev Med Interne. 2005;26(10):835\u20136.","journal-title":"Rev Med Interne"},{"issue":"3","key":"720_CR32","first-page":"162","volume":"14","author":"P Loiseau","year":"1985","unstructured":"Loiseau P, Guyot M, Pautrizel B, Vincon G, Albin H. Carbamazepine intoxication caused by the interaction of carbamazepine-erythromycin. Presse Med. 1985;14(3):162.","journal-title":"Presse Med"},{"issue":"6","key":"720_CR33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1542\/peds.80.6.951","volume":"80","author":"AJ Macnab","year":"1987","unstructured":"Macnab AJ, Robinson JL, Adderly RJ, D\u2019Orsogna L. Heart block secondary to erythromycin-induced carbamazepine toxicity. Pediatrics. 1987;80(6):951\u20133.","journal-title":"Pediatrics"},{"issue":"1","key":"720_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archpedi.1995.02170130101025","volume":"149","author":"CE Stafstrom","year":"1995","unstructured":"Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR. Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med. 1995;149(1):99\u2013101.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"720_CR35","first-page":"513","volume":"43","author":"T Tagawa","year":"1989","unstructured":"Tagawa T, Mimaki T, Ono J, Tanaka J, Suzuki Y, Itagaki T, et al. Erythromycin-induced carbamazepine intoxication in two epileptic children. Jpn J Psychiatry Neurol. 1989;43:513\u20134.","journal-title":"Jpn J Psychiatry Neurol."},{"issue":"9","key":"720_CR36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/BF01957582","volume":"151","author":"F Viani","year":"1992","unstructured":"Viani F, Claris-Appiani A, Rossi LN, Giani M, Romeo A. Severe hepatorenal failure in a child receiving carbamazepine and erythromycin F. Eur J Pediatr. 1992;151(9):715.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"720_CR37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/00006454-198706000-00021","volume":"6","author":"RC Woody","year":"1987","unstructured":"Woody RC, Kearns GL, Bolyard KJ. Carbamazepine intoxication following the use of erythromycin\u00a0in\u00a0children. Pediatr Infect Dis J. 1987;6(6):578\u20139.","journal-title":"Pediatr Infect Dis J."},{"issue":"4","key":"720_CR38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004850-199707000-00007","volume":"12","author":"N Yasui","year":"1997","unstructured":"Yasui N, Otani K, Kaneko S, Shimoyama R, Ohkubo T, Sugawara K. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. Int Clin Psychopharmacol. 1997;12(4):225\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"720_CR39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/000992288702600302","volume":"26","author":"BJ Zitelli","year":"1987","unstructured":"Zitelli BJ, Howrie DL, Altman H, Maroon TJ. Erythromycin-induced drug interactions. An illustrative case and review of the literature. Clin Pediatr (Phila). 1987;26(3):117\u20139.","journal-title":"Clin Pediatr (Phila)"},{"issue":"3","key":"720_CR40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.kjms.2016.12.001","volume":"33","author":"CR Huang","year":"2017","unstructured":"Huang CR, Lin CH, Hsiao SC, Chen NC, Tsai WC, Chen SD, et al. Drug interaction between valproic acid and carbapenems in patients with epileptic seizures. Kaohsiung J Med Sci. 2017;33(3):130\u20136.","journal-title":"Kaohsiung J Med Sci"},{"issue":"8","key":"720_CR41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clineuro.2011.05.007","volume":"113","author":"S Mink","year":"2011","unstructured":"Mink S, Muroi C, Seule M, Bjeljac M, Keller E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2011;113(8):644\u20138.","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"720_CR42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/FTD.0b013e318260f7b3","volume":"34","author":"MK Park","year":"2012","unstructured":"Park MK, Lim KS, Kim TE, Han HK, Yi SJ, Shin KH, et al. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. Ther Drug Monit. 2012;34(5):599\u2013603.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"720_CR43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1345\/aph.1K079","volume":"41","author":"I Spriet","year":"2007","unstructured":"Spriet I, Goyens J, Meersseman W, Wilmer A, Willems L, Van Paesschen W. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007;41(7):1130\u20136.","journal-title":"Ann Pharmacother"},{"issue":"2\u20134","key":"720_CR44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1515\/DMDI.2009.24.2-4.153","volume":"24","author":"JK Tobin","year":"2009","unstructured":"Tobin JK, Golightly LK, Kick SD, Jones MA. Valproic acid-carbapenem interaction: report of six cases and a review of the literature. Drug Metabol Drug Interact. 2009;24(2\u20134):153\u201382.","journal-title":"Drug Metabol Drug Interact."},{"issue":"2","key":"720_CR45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/jcpt.12501","volume":"42","author":"ZP Wen","year":"2017","unstructured":"Wen ZP, Fan SS, Du C, Yin T, Zhou BT, Peng ZF, et al. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther. 2017;42(2):221\u20137.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"720_CR46","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/0091270009334377","volume":"49","author":"S Haroutiunian","year":"2009","unstructured":"Haroutiunian S, Ratz Y, Rabinovich B, Adam M, Hoffman A. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. J Clin Pharmacol. 2009;49(11):1363\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"720_CR47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejpn.2014.12.010","volume":"19","author":"MC Miranda Herrero","year":"2015","unstructured":"Miranda Herrero MC, Alcaraz Romero AJ, Escudero Vilaplana V, Fern\u00e1ndez Lafever SN, Fern\u00e1ndez-Llamazares CM, Barredo Valderrama E, et al. Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics? Eur J Paediatr Neurol. 2015;19(2):155\u201361.","journal-title":"Eur J Paediatr Neurol."},{"issue":"5","key":"720_CR48","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","volume":"38","author":"CC Wu","year":"2016","unstructured":"Wu CC, Pai TY, Hsiao FY, Shen LJ, Wu FL. The effect of different carbapenem antibiotics (ertapenem, imipenem\/cilastatin, and meropenem) on serum valproic acid concentrations. Ther Drug Monit. 2016;38(5):587\u201392.","journal-title":"Ther Drug Monit"},{"issue":"20","key":"720_CR49","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.medcli.2008.06.018","volume":"132","author":"AM Borobia","year":"2009","unstructured":"Borobia AM, Fudio S, Carcas Sansu\u00e1n AJ. Valproate-meropenem co-administration, an example of information shortcomings in relevant drug interactions [in Spanish]. Med Clin (Barc). 2009;132(20):803\u20134.","journal-title":"Med Clin (Barc)."},{"issue":"1","key":"720_CR50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nrl.2011.03.008","volume":"27","author":"M V\u00e9lez D\u00edaz-Pallar\u00e9s","year":"2012","unstructured":"V\u00e9lez D\u00edaz-Pallar\u00e9s M, Delgado Silveira E, Alvarez D\u00edaz AM, P\u00e9rez Men\u00e9ndez-Conde C, Vicente Oliveros N, Bermejo Vicedo T. Analysis of the valproic acid-meropenem interaction in hospitalised patients. Neurologia. 2012;27(1):34\u20138.","journal-title":"Neurologia."},{"issue":"3","key":"720_CR51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4067\/S0034-98872014000300019","volume":"142","author":"D Berardi","year":"2014","unstructured":"Berardi D, Clemente R, Finn BC, Bruetman JE, Young P. Not to forget interaction between meropenem and valproic acid. Rev Med Chil. 2014;142(3):400\u20131.","journal-title":"Rev Med Chil"},{"issue":"5","key":"720_CR52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1130-6343(06)73997-6","volume":"30","author":"MA Cabanes Mariscal","year":"2006","unstructured":"Cabanes Mariscal MA, S\u00e1nchez L\u00f3pez P, Alvarez Herranz P, Chamorro Merino G. Pharmacokinetic interaction between valproic acid and ertapenem. Farm Hosp. 2006;30(5):313\u20135.","journal-title":"Farm Hosp."},{"issue":"9","key":"720_CR53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00134-005-2695-0","volume":"31","author":"D Clause","year":"2005","unstructured":"Clause D, Decleire PY, Vanbinst R, Soyer A, Hantson P. Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Med. 2005;31(9):1293\u20134.","journal-title":"Intensive Care Med"},{"issue":"3","key":"720_CR54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4067\/S0716-10182012000300018","volume":"29","author":"C Gonz\u00e1lez","year":"2012","unstructured":"Gonz\u00e1lez C, Villena R. Pharmacological interaction between meropenem and valproic acid: a report of two cases. Rev Chilena Infectol. 2012;29(3):353\u20135.","journal-title":"Rev Chilena Infectol."},{"issue":"5","key":"720_CR55","first-page":"338","volume":"27","author":"SG Lee","year":"2007","unstructured":"Lee SG, Kim JH, Joo JY, Kwon OH. Seven cases of decreased serum valproic acid concentration during concomitant use of carbapenem antibiotics [in Korean]. Korean J Lab Med. 2007;27(5):338\u201343.","journal-title":"Korean J Lab Med"},{"issue":"4","key":"720_CR56","first-page":"258","volume":"27","author":"F Llinares Tello","year":"2003","unstructured":"Llinares Tello F, Bosacoma Ros N, Hern\u00e1ndez Prats C, Climent Grana E, Selva Otaolaurruchi J, Ordov\u00e1s Baines JP. Pharmacokinetic interaction between valproic acid and carbapenem-like antibiotics: a discussion of three cases. Farm Hosp. 2003;27(4):258\u201363.","journal-title":"Farm Hosp."},{"issue":"3","key":"720_CR57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/JCP.0000000000000325","volume":"35","author":"GP Molnar","year":"2015","unstructured":"Molnar GP, Stephens KJ, George LV, Stewart JT. A critical interaction between ertapenem and valproic acid. J Clin Psychopharmacol. 2015;35(3):348\u201350.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"720_CR58","doi-asserted-by":"crossref","first-page":"560.e1","DOI":"10.1016\/j.genhosppsych.2010.03.004","volume":"32","author":"AJ Muzyk","year":"2010","unstructured":"Muzyk AJ, Candeloro CL, Christopher EJ. Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder. Gen Hosp Psychiatry. 2010;32(5):560.e1\u20133.","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"720_CR59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pediatrneurol.2004.03.014","volume":"31","author":"E Nacarkucuk","year":"2004","unstructured":"Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004;31(3):232\u20134.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"720_CR60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/39.2.295","volume":"39","author":"K Nagai","year":"1997","unstructured":"Nagai K, Shimizu T, Togo A, Takeya M, Yokomizo Y, Sakata Y, Matsuishi T, Kato H. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem\/betamipron. J Antimicrob Chemother. 1997;39(2):295\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"720_CR61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JCP.0000000000000433","volume":"36","author":"M Paulzen","year":"2016","unstructured":"Paulzen M, Eap CB, Gr\u00fcnder G, Kuzin M. Pharmacokinetic interaction between valproic acid, meropenem, and risperidone. J Clin Psychopharmacol. 2016;36(1):90\u20132.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"720_CR62","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1130-6343(06)73999-X","volume":"30","author":"M Perea Falomir","year":"2006","unstructured":"Perea Falomir M, Roura Poch P, Higueruelo Demas\u00f3n S, Garc\u00eda Gil VJ. Pharmacokinetic interaction between valproic acid and imipenem. Farm Hosp. 2006;30(5):316\u20137.","journal-title":"Farm Hosp."},{"issue":"2","key":"720_CR63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.anpedi.2008.08.009","volume":"70","author":"V San Antonio Arce","year":"2009","unstructured":"San Antonio Arce V, Joyanes Abancens B. Meropenem and valproic acid. An interaction to remember. An Pediatr (Barc). 2009;70(2):193\u20134.","journal-title":"An Pediatr (Barc)"},{"issue":"2","key":"720_CR64","first-page":"293","volume":"95","author":"W Suntimaleeworakul","year":"2012","unstructured":"Suntimaleeworakul W, Patharachayakul S, Chusri S. Drug interaction between valproic acid and meropenem: a case report. J Med Assoc Thai. 2012;95(2):293\u20135.","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"720_CR65","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11096-013-9763-2","volume":"35","author":"H Yoon","year":"2013","unstructured":"Yoon H, Kim DH. Unusual drug reaction between valproate sodium and meropenem. Int J Clin Pharm. 2013;35(3):316\u20138.","journal-title":"Int J Clin Pharm."},{"issue":"3","key":"720_CR66","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1345\/aph.1E358","volume":"39","author":"FJ Coves-Orts","year":"2005","unstructured":"Coves-Orts FJ, Borr\u00e1s-Blasco J, Navarro-Ruiz A, Murcia-L\u00f3pez A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005;39(3):533\u20137.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"720_CR67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.medcli.2010.06.026","volume":"137","author":"MI Fern\u00e1ndez Garc\u00eda","year":"2011","unstructured":"Fern\u00e1ndez Garc\u00eda MI, Fern\u00e1ndez de la Puebla Gim\u00e9nez R\u00c1, Garc\u00eda Olid B, Torres Degay\u00f3n V. Meropenem decreases valproate plasmatic concentrations. Med Clin (Barc). 2011;137(1):43\u20134.","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"720_CR68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.amjopharm.2009.02.005","volume":"7","author":"J Gu","year":"2009","unstructured":"Gu J, Huang Y. Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient. Am J Geriatr Pharmacother. 2009;7(1):26\u201333.","journal-title":"Am J Geriatr Pharmacother."},{"issue":"1","key":"720_CR69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0025-7753(04)74403-6","volume":"123","author":"A P\u00e9rez Plasencia","year":"2004","unstructured":"P\u00e9rez Plasencia A, Soy D, Nicolas JM. Pharmacokinetic interaction between valproic acid and meropenem. Med Clin (Barc). 2004;123(1):38\u20139.","journal-title":"Med Clin (Barc)."},{"issue":"1","key":"720_CR70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1695-4033(06)70016-9","volume":"64","author":"F Sala Pi\u00f1ol","year":"2006","unstructured":"Sala Pi\u00f1ol F, Padull\u00e9s Zamora N, Hidalgo Albert E, Clemente Bautista S, Caba\u00f1as Poy MJ, Oliveras Arenas M, et al. Pharmacokinetic interaction between valproic acid and meropenem. An Pediatr (Barc). 2006;64(1):93\u20135.","journal-title":"An Pediatr (Barc)."},{"issue":"1","key":"720_CR71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5414\/CP202188","volume":"53","author":"A Shihyakugari","year":"2015","unstructured":"Shihyakugari A, Miki A, Nakamoto N, Satoh H, Sawada Y. First case report of suspected onset of convulsive seizures due to co-administration of valproic acid and tebipenem. Int J Clin Pharmacol Ther. 2015;53(1):92\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"720_CR72","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1345\/aph.1Q165","volume":"45","author":"I Spriet","year":"2011","unstructured":"Spriet I, Willems L. No interaction between valproate and meropenem in a cirrhotic patient. Ann Pharmacother. 2011;45(9):1167\u20138.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"720_CR73","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4212\/cjhp.v63i4.936","volume":"63","author":"D Bates","year":"2010","unstructured":"Bates D, Parkins M, Duggan K. Ertapenem-induced reduction in valproate levels: case report and review of the literature. Can J Hosp Pharm. 2010;63(4):315\u201322.","journal-title":"Can J Hosp Pharm."},{"issue":"8","key":"720_CR74","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1592\/phco.27.8.1202","volume":"27","author":"JL Lunde","year":"2007","unstructured":"Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy. 2007;27(8):1202\u20135.","journal-title":"Pharmacotherapy."},{"issue":"5","key":"720_CR75","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/08830738050200051401","volume":"20","author":"M Santucci","year":"2005","unstructured":"Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased serum valproate during meropenem therapy. J Child Neurol. 2005;20(5):456\u20137.","journal-title":"J Child Neurol"},{"issue":"4","key":"720_CR76","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00007691-199808000-00008","volume":"20","author":"T Yamagata","year":"1998","unstructured":"Yamagata T, Momoi MY, Murai K, Ikematsu K, Suwa K, Sakamoto K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit. 1998;20(4):396\u2013400.","journal-title":"Ther Drug Monit"},{"key":"720_CR77","first-page":"126","volume":"4","author":"A Alem\u00e1n","year":"2012","unstructured":"Alem\u00e1n A, Mart\u00edn Romano L. Valproic acid and meropenem, a bad association. Description of two cases and review of the literature. Neurol Arg. 2012;4:126\u201331.","journal-title":"Neurol Arg"},{"issue":"2","key":"720_CR78","first-page":"207","volume":"46","author":"K Bachmann","year":"1984","unstructured":"Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L. Single dose phenytoin clearance during erythromycin treatment. Res Commun Chem Pathol Pharmacol. 1984;46(2):207\u201317.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"3","key":"720_CR79","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2125.1988.tb05285.x","volume":"26","author":"RW Milne","year":"1988","unstructured":"Milne RW, Coulthard K, Nation RL, Penna AC, Roberts G, Sansom LN. Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin. Br J Clin Pharmacol. 1988;26(3):330\u20133.","journal-title":"Br J Clin Pharmacol"},{"key":"720_CR80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.0954-6820.1979.tb00729.x","volume":"624","author":"JM Hansen","year":"1979","unstructured":"Hansen JM, Kampmann JP, Siersbaek-Nielsen K, Lumholtz IB, Arr\u00f8e M, Abildgaard U, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl. 1979;624:106\u201310.","journal-title":"Acta Med Scand Suppl."},{"issue":"4","key":"720_CR81","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2125.2010.03866.x","volume":"71","author":"T Antoniou","year":"2011","unstructured":"Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim\/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. Br J Clin Pharmacol. 2011;71(4):544\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"720_CR82","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.2147\/DDDT.S89464","volume":"9","author":"SY Lee","year":"2015","unstructured":"Lee SY, Huh W, Jung JA, Yoo HM, Ko JW, Kim JR. Effects of amoxicillin\/clavulanic acid on the pharmacokinetics of valproic acid. Drug Des Devel Ther. 2015;9:4559\u201363.","journal-title":"Drug Des Devel Ther."},{"issue":"2","key":"720_CR83","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/j.1552-4604.1998.tb04409.x","volume":"38","author":"RC Sachdeo","year":"1998","unstructured":"Sachdeo RC, Narang-Sachdeo S, Montgomery PA, Shumaker RC, Perhach JL, Lyness WH, et al. Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy. J Clin Pharmacol. 1998;38(2):184\u201390.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"720_CR84","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0404.1992.tb05051.x","volume":"86","author":"T Ker\u00e4nen","year":"1992","unstructured":"Ker\u00e4nen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand. 1992;86(2):120\u20133.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"720_CR85","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2125.2009.03593.x","volume":"69","author":"R Santucci","year":"2010","unstructured":"Santucci R, Fothergill H, Laugel V, Perville A, De Saint Martin A, Gerout AC, et al. The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy. Br J Clin Pharmacol. 2010;69(3):314\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"720_CR86","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40261-015-0281-y","volume":"35","author":"ML Chew","year":"2015","unstructured":"Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial. Clin Drug Investig. 2015;35(5):299\u2013305.","journal-title":"Clin Drug Investig."},{"issue":"11","key":"720_CR87","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/009127009803801110","volume":"38","author":"MS Thomsen","year":"1998","unstructured":"Thomsen MS, Groes L, Agers\u00f8 H, Kruse T. Lack of pharmacokinetic interaction between tiagabine and erythromycin. J Clin Pharmacol. 1998;38(11):1051\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"720_CR88","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/s-2007-1025555","volume":"202","author":"S Harder","year":"1990","unstructured":"Harder S, Schneider W, Bae ZU, Bock U, Zielen S. Undesirable drug reactions in simultaneous administration of high-dosage phenobarbital and beta-lactam antibiotics. Klin Padiatr. 1990;202(6):404\u20137.","journal-title":"Klin Padiatr"},{"issue":"2","key":"720_CR89","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/106002809202600225","volume":"26","author":"ML Dillard","year":"1992","unstructured":"Dillard ML, Fink RM, Parkerson R. Ciprofloxacin-phenytoin interaction. Ann Pharmacother. 1992;26(2):263.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"720_CR90","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/106002809302701020","volume":"27","author":"RL Hull","year":"1993","unstructured":"Hull RL. Possible phenytoin-ciprofloxacin interaction. Ann Pharmacother. 1993;27(10):1283.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"720_CR91","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1345\/aph.16267c","volume":"32","author":"R McLeod","year":"1998","unstructured":"McLeod R, Trinkle R. Comment: unexpectedly low phenytoin concentration in a patient receiving ciprofloxacin. Ann Pharmacother. 1998;32(10):1110\u20131.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"720_CR92","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1345\/aph.17288a","volume":"33","author":"MJ Otero","year":"1999","unstructured":"Otero MJ, Mor\u00e1n D, Valverde MP. Interaction between phenytoin and ciprofloxacin. Ann Pharmacother. 1999;33(2):251\u20132.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"720_CR93","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/106002809703100111","volume":"31","author":"PT Pollak","year":"1997","unstructured":"Pollak PT, Slayter KL. Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin. Ann Pharmacother. 1997;31(1):61\u20134.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"720_CR94","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1177\/106002809703101222","volume":"31","author":"PT Pollak","year":"1997","unstructured":"Pollak PT, Slayter KL. Comment: ciprofloxacin-phenytoin interaction. Ann Pharmacother. 1997;31(12):1549\u201350.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"720_CR95","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/pdp.21.5.477.484","volume":"21","author":"D Mileusnic","year":"2002","unstructured":"Mileusnic D, Donoghue ER, Lifschultz BD. Pathological case of the month: sudden death in a child as a result of pancreatitis during valproic acid therapy. Pediatr Pathol Mol Med. 2002;21(5):477\u201384.","journal-title":"Pediatr Pathol Mol Med."},{"issue":"1","key":"720_CR96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF03160902","volume":"1","author":"JA Lowry","year":"2005","unstructured":"Lowry JA, et al. Unusual presentation of iatrogenic phenytoin toxicity in a newborn. J Med Toxicol. 2005;1(1):26\u20139.","journal-title":"J Med Toxicol."},{"issue":"6","key":"720_CR97","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.medcli.2017.03.046","volume":"149","author":"JV Catal\u00e1 Ripoll","year":"2017","unstructured":"Catal\u00e1 Ripoll JV, Domingo Chiva E, Marco del R\u00edo J. Interaction between levofloxacin and phenytoin: report of two cases. Med Clin (Barc). 2017;149(6):278\u20139.","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"720_CR98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-102-4-559_2","volume":"102","author":"MA Gillman","year":"1985","unstructured":"Gillman MA, Sandyk R. Phenytoin toxicity and co-trimoxazole. Ann Intern Med. 1985;102(4):559.","journal-title":"Ann Intern Med"},{"issue":"Suppl 8","key":"720_CR99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/epi.12418","volume":"54","author":"G Avanzini","year":"2013","unstructured":"Avanzini G, Depaulis A, Tassinari A, de Curtis M. Do seizures and epileptic activity worsen epilepsy and deteriorate cognitive function? Epilepsia. 2013;54(Suppl 8):14\u201321.","journal-title":"Epilepsia."},{"issue":"1","key":"720_CR100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jsmc.2015.10.008","volume":"11","author":"L Kataria","year":"2016","unstructured":"Kataria L, Vaughn BV. Sleep and Epilepsy. Sleep Med Clin. 2016;11(1):25\u201338.","journal-title":"Sleep Med Clin."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0720-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:15:42Z","timestamp":1775261742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0720-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0720-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,7]]},"assertion":[{"value":"7 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by funds from the Regional Centre of Pharmacovigilance of Lombardy (to EC); the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA; to EC); and the Italian Ministry of Health (Ricerca Corrente 2018; to MP). All funding is gratefully acknowledged. The public funding institutions had no role in any part of the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Carla Carnovale, Marco Pozzi, Faizan Mazhar, Giulia Mosini, Marta Gentili, Gabri\u00eblla G.A.M. Peeters, Emilio Clementi and Sonia Radice have no conflicts of interest to declare that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}